SUMO1 is a so-called chaperone protein that regulates the activity of key transporter genes It has been deternined that SUM01 is decreased in the failing heart suggesting the protien may play a critical role in the pathogenesis of heart failure. The founding of Sumocor LLC and the firm's research focus comes out of, and builds on, the research findings of the firm's President and CEO at the Icahn School of Medicine at Mount Sinai when it was discovered that if SUMO1 was injected into failing preclinical models via gene therapy, a significant improvement of cardiac function was observed.
